|
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
 9th Annual Needham Healthcare Conference
June 10, 2010
2:00 pm EDT (11:00 am PDT)
Click here for the webcast.
2009 Annual Report
2010 Proxy Statement
August 06, 2010
Telik Announces Second Quarter 2010 Financial Results
July 12, 2010
Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
|
